Previous 10 | Next 10 |
Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference PR Newswire CAMBRIDGE, Mass. , Feb. 1, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisel...
2024-01-16 07:00:00 ET Summary Small cap stocks surged in the final two months of the year as the 10-year yield reversed direction. The Fed's actions in 2024 will determine the prospects for small cap stocks, with a rate cut in March improving their prospects. Small caps may f...
2024-01-10 07:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-08 12:21:22 ET More on Nuvalent Nuvalent: Strong Data, But Properly Valued Nuvalent GAAP EPS of -$0.59 misses by $0.01 Nuvalent prices $300 million stock offering Seeking Alpha’s Quant Rating on Nuvalent Historical earnings data for Nuv...
Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones PR Newswire Targeting first approved product in 2026 towards realizing mission of bringing new, potential best-in-class treatments to patients with cancer Well-capitalized to support OnTar...
2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...
2023-12-24 21:14:00 ET Summary Nuvalent's stock has nearly doubled after positive phase 1 data from its second candidate, NVL-565, targeting ALK-positive NSCLC. The preliminary data showed early anti-tumor activity in heavily pre-treated patients, patients with ALK resistance muta...
Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Dec. 21, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapie...
2023-12-20 10:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-15 07:00:00 ET Summary Biotech stocks, long burdened by concerns over rising yields, are poised for improvement as the 10-year yield may have peaked, signaling a potential upswing in the industry's fortunes. The recent uptrend in the 10-year yield, peaking around 5% in Oct...
News, Short Squeeze, Breakout and More Instantly...
Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor PR Newswire CAMBRIDGE, Mass. , July 22, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company foc...
Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024 PR Newswire CAMBRIDGE, Mass. , July 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharma...
Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer PR Newswire CAMBRIDGE, Mass. , July 11, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely target...